New Investigation of Ventrus Biosciences, Inc. (NASDAQ: VTUS)

Zeldes & Haeggquist, LLP has commenced an investigation into Ventrus Biosciences, Inc. (“Ventrus”), to determine whether it has violated securities laws by issuing false and misleading statements to its shareholders. Ventrus is a specialty pharmaceutical company that focuses on the development of prescription drugs for gastrointestinal disorders.  On June 25, 2012, Ventrus announced the results…